Update on the role of probiotics in the therapy of pediatric inflammatory bowel disease

被引:32
作者
Guandalini, Stefano [1 ]
机构
[1] Univ Chicago, Comer Childrens Hosp, Sect Pediat Gastroenterol Hepatol & Nutr, Chicago, IL 60637 USA
关键词
Bifidobacterium; Crohn's; IBD; inflammatory bowel disease; Lactobacillus; pouchitis; probiotics; Saccharomyces; ulcerative colitis; VSL#3; CROHNS-DISEASE; ESCHERICHIA-COLI; SACCHAROMYCES-BOULARDII; ULCERATIVE-COLITIS; DOUBLE-BLIND; LACTOBACILLUS-CASEI; EPITHELIAL BARRIER; TIGHT JUNCTION; IN-VITRO; BIFIDOBACTERIUM-LACTIS;
D O I
10.1586/ECI.09.70
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
071005 [微生物学]; 100108 [医学免疫学];
摘要
Probiotics have had many applications in the past few years, and inflammatory conditions of the GI tract - including chronic disorders such as inflammatory bowel disease (IBD) - have received the most attention by investigators. In fact, the experimental basis to expect clinical efficacy of probiotics in IBD is quite robust. In spite of this however, only minimal evidence of benefit by any probiotic is currently available in Crohn's disease, either in adult or in pediatric populations. In ulcerative colitis, on the other hand, several probiotic formulations and especially the proprietary preparation VSL#3 (a high-concentration mixture) have been found effective as adjuvant therapy, both in inducing and maintaining remission.
引用
收藏
页码:47 / 54
页数:8
相关论文
共 61 条
[1]
Therapeutic Potential of Two Probiotics in Inflammatory Bowel Disease as observed in the Trinitrobenzene Sulfonic Acid Model of Colitis [J].
Amit-Romach, Einat ;
Uni, Zehava ;
Reifen, Ram .
DISEASES OF THE COLON & RECTUM, 2008, 51 (12) :1828-1836
[2]
Treatment with biologic therapies and the risk of cancer in patients with IBD [J].
Biancone, Livia ;
Calabrese, Emma ;
Petruzziello, Carmelina ;
Pallone, Francesco .
NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2007, 4 (02) :78-91
[3]
A randomized, double-blind trial of lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease [J].
Bousvaros, A ;
Guandalini, S ;
Baldassano, RN ;
Botelho, C ;
Evans, J ;
Ferry, GD ;
Goldin, B ;
Hartigan, L ;
Kugathasan, S ;
Levy, J ;
Murray, KE ;
Oliva-Hemker, M ;
Rosh, JR ;
Tolia, V ;
Zholudev, A ;
Vanderhoof, JA ;
Hibberd, PL .
INFLAMMATORY BOWEL DISEASES, 2005, 11 (09) :833-839
[4]
Therapeutic effects of four strains of probiotics on experimental colitis in mice [J].
Chen, Lin-Lin ;
Wang, Xue-Hong ;
Cui, Yi ;
Lian, Guang-Hui ;
Zhang, Jie ;
Ouyang, Chun-Hui ;
Lu, Fang-Gen .
WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (03) :321-327
[5]
Failure of synbiotic 2000 to prevent postoperative recurrence of Crohn's disease [J].
Chermesh, Irit ;
Tamir, Ada ;
Reshef, Ron ;
Chowers, Yehuda ;
Suissa, Alain ;
Katz, Dalia ;
Gelber, Moshe ;
Halpern, Zamir ;
Bengmark, Stig ;
Eliakim, Rami .
DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (02) :385-389
[6]
Lactobacillus casei prevents the development of dextran sulphate sodium-induced colitis in Toll-like receptor 4 mutant mice [J].
Chung, Y. W. ;
Choi, J. H. ;
Oh, T. -Y. ;
Eun, C. S. ;
Han, D. S. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2008, 151 (01) :182-189
[7]
Role of commercial probiotic strains against human pathogen adhesion to intestinal mucus [J].
Collado, M. C. ;
Meriluoto, J. ;
Salminen, S. .
LETTERS IN APPLIED MICROBIOLOGY, 2007, 45 (04) :454-460
[8]
Production of bacteriocin-like inhibitory compounds by human fecal Bifidobacterium strains [J].
Collado, MC ;
Hernández, M ;
Sanz, Y .
JOURNAL OF FOOD PROTECTION, 2005, 68 (05) :1034-1040
[9]
Bacteriocins: Developing innate immunity for food [J].
Cotter, PD ;
Hill, C ;
Ross, RP .
NATURE REVIEWS MICROBIOLOGY, 2005, 3 (10) :777-788
[10]
Saccharomyces boulardii inhibits inflammatory bowel disease by trapping T cells in mesenteric lymph nodes [J].
Dalmasso, Guillaume ;
Cottrez, Francoise ;
Imbert, Veronique ;
Lagadec, Patricia ;
Peyron, Jean-Francois ;
Rampal, Patrick ;
Czerucka, Dorota ;
Groux, Herve .
GASTROENTEROLOGY, 2006, 131 (06) :1812-1825